{
  "id": 14329485,
  "title": "Liquidia (NASDAQ:LQDA) CMO Rajeev Saggar disposes of $262,528 in stock",
  "url": "https://urgent.news/2026/10/14/liquidia-nasdaq-lqda-cmo-rajeev-saggar-disposes-of-262-528-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-14T00:31:07.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/liquidia-nasdaqlqda-cmo-rajeev-saggar-disposes-of-262528-in-stock-93CH-4947784"
  },
  "original_language": "en",
  "account": null,
  "summary": "Liquidia (NASDAQ:LQDA) Chief Medical Officer Rajeev Saggar disposed of $262,528 worth of company stock on October 12, 2026, selling 9,218 shares at $28.48 per share. This transaction, executed under a Rule 10b5-1 plan, came after he had acquired additional shares earlier in the week. The sale was made to cover taxes from restricted stock units and performance stock units granted to Saggar starting in 2023. Despite recent price declines, Liquidia maintains a strong financial health score with impressive gross profit margins and a market capitalization of $2.48 billion. The stock is currently undervalued according to InvestingPro, and Dr. Saggar holds a total of 126,368 shares directly, with an additional 15,099 shares held indirectly. Recent developments include patent litigation with United Therapeutics, which has led to adjustments in analyst ratings and price targets.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}